Trulive Medical key facts
- Manufacturer of medical instruments designed to cure structural heart diseases.
- It has raised $28.6M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Suzhou Oriza Holdings Corporation, Oriental Fortune Capital, SDIC Unity Capital, Proxima Ventures (China), Xiamen C&D Corporation — 22 tracked in total.
- Status: Privately Held (backing).
Who backs Trulive Medical
22+- ·The complete investor list: 22 names
- ·Watch Trulive Medical: the Monday email on marks, rounds and moves
Trulive Medical funding rounds
No funding rounds for Trulive Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Trulive Medical investors
22 investors are on record for Trulive Medical, including Suzhou Oriza Holdings Corporation, Oriental Fortune Capital, SDIC Unity Capital and Proxima Ventures (China).
About Trulive Medical
Manufacturer of medical instruments designed to cure structural heart diseases. The company develops bicuspid valve substitute solutions for the four major disease areas of heart valve disease, heart failure, peripheral artery disease, and coronary artery disease, thereby providing medical providers with effective technology and equipment support.
- Sector
- Healthcare
- HQ
- Nantong, China
- Founded
- 2019
- Employees
- 200
- Website
- trulive.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Trulive Medical doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.